Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19

Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19 Publisher Pubmed

Sahebnasagh A¹ ; Saghafi F² ; Safdari M³ ; Khataminia M⁴ ; Sadremomtaz A⁵ ; Talaei Z⁶ ; Rezai Ghaleno H⁷ ; Bagheri M⁸ ; Habtemariam S⁹ ; Avan R¹⁰

Show Affiliations

1. Department of Internal Medicine, Clinical Research Center, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
2. Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3. Department of Orthopedic Surgery, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
4. Student Research Committee, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
5. XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, Netherlands
6. Department of Chemistry, Faculty of Science, Shahid Rajaee Teacher Training University, Tehran, Iran
7. Department of Surgery, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
8. Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran
9. Pharmacognosy Research Laboratories and Herbal Analysis Services, School of Science, University of Greenwich, Kent, United Kingdom
10. Department of Clinical Pharmacy, Medical Toxicology and Drug Abuse Research Center (MTDRC), Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran

Source: Journal of Clinical Pharmacy and Therapeutics Published:2020

Abstract

What is known and objective: This article summarizes the effects of sivelestat on acute lung injury/acute respiratory distress syndrome (ALI/ARDS) or ARDS with coagulopathy, both of which are frequently seen in patients with COVID-19. Comment: COVID-19 patients are more susceptible to thromboembolic events, including disseminated intravascular coagulation (DIC). Various studies have emphasized the role of neutrophil elastase (NE) in the development of DIC in patients with ARDS and sepsis. It has been shown that NE inhibition by sivelestat mitigates ALI through amelioration of injuries in alveolar epithelium and vascular endothelium, as well as reversing the neutrophil-mediated increased vascular permeability. What is new and conclusions: Sivelestat, a selective NE inhibitor, has not been evaluated for its possible therapeutic effects against SARS-CoV-2 infection. Based on its promising beneficial effects in underlying complications of COVID-19, sivelestat could be considered as a promising modality for better management of COVID-19–induced ALI/ARDS or coagulopathy. © 2020 John Wiley & Sons Ltd

Related Docs

View other Related Docs

1. Covid-19 and Multiorgan Failure: A Narrative Review on Potential Mechanisms, Journal of Molecular Histology (2020)

2. Complement Inhibition: A Possible Therapeutic Approach in the Fight Against Covid-19, Reviews in Medical Virology (2022)

3. Pathological Effects of Sars-Cov-2 on Hematological and Immunological Cells: Alterations in Count, Morphology, and Function, Pathology Research and Practice (2022)

4. A Perspective on Erythropoietin As a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients With Covid-19, Archives of Medical Research (2020)

5. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)

6. Ten Challenging Questions About Sars-Cov-2 and Covid-19, Expert Review of Respiratory Medicine (2020)

7. Mesenchymal Stromal/Stem Cells (Mscs) and Msc-Derived Extracellular Vesicles in Covid-19-Induced Ards: Mechanisms of Action, Research Progress, Challenges, and Opportunities, International Immunopharmacology (2021)

8. Pharmacotherapy Consideration of Thrombolytic Medications in Covid-19-Associated Ards, Journal of Intensive Care (2022)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (15)

Mohammadreza Salehi (5)

Style	Citing Format
MLA	Sahebnasagh A, et al.. "Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19." Journal of Clinical Pharmacy and Therapeutics, vol. 45, no. 6, 2020, pp. 1515-1519.
APA	Sahebnasagh A, Saghafi F, Safdari M, Khataminia M, Sadremomtaz A, Talaei Z, Rezai Ghaleno H, Bagheri M, Habtemariam S, Avan R (2020). Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19. Journal of Clinical Pharmacy and Therapeutics, 45(6), 1515-1519.
Chicago	Sahebnasagh A, Saghafi F, Safdari M, Khataminia M, Sadremomtaz A, Talaei Z, Rezai Ghaleno H, Bagheri M, Habtemariam S, Avan R. "Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19." Journal of Clinical Pharmacy and Therapeutics 45, no. 6 (2020): 1515-1519.
Harvard	Sahebnasagh A et al. (2020) 'Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19', Journal of Clinical Pharmacy and Therapeutics, 45(6), pp. 1515-1519.
Vancouver	Sahebnasagh A, Saghafi F, Safdari M, Khataminia M, Sadremomtaz A, Talaei Z, et al.. Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19. Journal of Clinical Pharmacy and Therapeutics. 2020;45(6):1515-1519.
BibTex	@article{ author = {Sahebnasagh A and Saghafi F and Safdari M and Khataminia M and Sadremomtaz A and Talaei Z and Rezai Ghaleno H and Bagheri M and Habtemariam S and Avan R}, title = {Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19}, journal = {Journal of Clinical Pharmacy and Therapeutics}, volume = {45}, number = {6}, pages = {1515-1519}, year = {2020} }
RIS	TY - JOUR AU - Sahebnasagh A AU - Saghafi F AU - Safdari M AU - Khataminia M AU - Sadremomtaz A AU - Talaei Z AU - Rezai Ghaleno H AU - Bagheri M AU - Habtemariam S AU - Avan R TI - Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19 JO - Journal of Clinical Pharmacy and Therapeutics VL - 45 IS - 6 SP - 1515 EP - 1519 PY - 2020 ER -

Style

Citing Format

MLA

Sahebnasagh A, et al.. "Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19." Journal of Clinical Pharmacy and Therapeutics, vol. 45, no. 6, 2020, pp. 1515-1519.

APA

Sahebnasagh A, Saghafi F, Safdari M, Khataminia M, Sadremomtaz A, Talaei Z, Rezai Ghaleno H, Bagheri M, Habtemariam S, Avan R (2020). Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19. Journal of Clinical Pharmacy and Therapeutics, 45(6), 1515-1519.

Chicago

Sahebnasagh A, Saghafi F, Safdari M, Khataminia M, Sadremomtaz A, Talaei Z, Rezai Ghaleno H, Bagheri M, Habtemariam S, Avan R. "Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19." Journal of Clinical Pharmacy and Therapeutics 45, no. 6 (2020): 1515-1519.

Harvard

Sahebnasagh A et al. (2020) 'Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19', Journal of Clinical Pharmacy and Therapeutics, 45(6), pp. 1515-1519.

Vancouver

Sahebnasagh A, Saghafi F, Safdari M, Khataminia M, Sadremomtaz A, Talaei Z, et al.. Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19. Journal of Clinical Pharmacy and Therapeutics. 2020;45(6):1515-1519.

BibTex

@article{ author = {Sahebnasagh A and Saghafi F and Safdari M and Khataminia M and Sadremomtaz A and Talaei Z and Rezai Ghaleno H and Bagheri M and Habtemariam S and Avan R}, title = {Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19}, journal = {Journal of Clinical Pharmacy and Therapeutics}, volume = {45}, number = {6}, pages = {1515-1519}, year = {2020} }

RIS

TY - JOUR
AU - Sahebnasagh A
AU - Saghafi F
AU - Safdari M
AU - Khataminia M
AU - Sadremomtaz A
AU - Talaei Z
AU - Rezai Ghaleno H
AU - Bagheri M
AU - Habtemariam S
AU - Avan R
TI - Neutrophil Elastase Inhibitor (Sivelestat) May Be a Promising Therapeutic Option for Management of Acute Lung Injury/Acute Respiratory Distress Syndrome or Disseminated Intravascular Coagulation in Covid-19
JO - Journal of Clinical Pharmacy and Therapeutics
VL - 45
IS - 6
SP - 1515
EP - 1519
PY - 2020
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract